Zatrol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zatrol

Quick Facts

Property Description
Active Ingredient Omeprazole
Form Delayed-Release Capsule / Tablet
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Reduction of gastric acid secretion
Origin Synthetic Compound

Zatrol: Definition, Active Ingredient, and Pharmacological Class

Zatrol is a synthetic, prescription-only medicine that functions as an anti-secretory drug, defined by its sole active ingredient, Omeprazole. This agent belongs to the Proton Pump Inhibitor (PPI) pharmacological class, placing it among the most effective antiulcer agents available. Omeprazole is a well-established compound chemically classified as a substituted benzimidazole. As such, the medicine works by targeting the root cause of excessive acid production.


Composition and Form: Delayed-Release Capsule

The medicine is typically delivered for oral administration in the form of a capsule containing enteric-coated pellets. This specific delayed-release formulation is essential for the medication's function: the coating protects the sensitive Omeprazole from immediate destruction by the gastric acid in the stomach, ensuring stability. This structure ensures the active ingredient safely bypasses the stomach and is fully absorbed in the small intestine, allowing it to reach the stomach's parietal cells where it can exert its effect.


General Purpose of an Anti-Secretory Drug

Zatrol's fundamental purpose is to achieve a profound and sustained diminution of basal and stimulated acid output in the stomach. Its mechanism involves the highly targeted, irreversible inhibition of the final step of acid production—the H^+K^+-ATPase enzyme system, or Proton Pump. The drug provides potent acid suppression. By consistently limiting the total amount of acid produced, this anti-secretory drug creates a protective environment within the gastrointestinal system, which is generally used to support the relief of persistent heartburn or uncomfortable acid reflux.

Regulatory References

  1. U.S. National Library of Medicine (MedlinePlus)

What side effects are possible with Zatrol?

Possible Side Effects and Safety Information

The safety profile of Zatrol (Omeprazole) is structured by regulatory documents that classify potential adverse reactions based on their official incidence rate and the body system affected.

Frequency-Classified Adverse Reactions

The official labeling organizes side effects into categories derived from clinical data:

  • Common Reactions (appearing in at least 1 in 100 people) primarily involve the nervous and gastrointestinal systems, including headache, abdominal pain, diarrhea, constipation, flatulence, and nausea/vomiting.
  • Uncommon Reactions (appearing in less than 1 in 100 people) include dizziness, insomnia, and dermatological events such as rash or pruritus.
  • Rare Reactions are documented to include serious events like low blood cell counts (leukopenia, thrombocytopenia) and severe hypersensitivity reactions (anaphylactic shock).

Serious Safety Considerations

Official regulatory texts explicitly list several rare but clinically significant adverse reactions. These include a potential risk of bone fracture of the hip, wrist, or spine, particularly with prolonged or high-dose therapy. Other serious reactions documented are interstitial nephritis (a form of kidney inflammation) and the risk of Clostridium difficile-associated diarrhea (CDAD).

Certain risks are associated with the duration of use. Hypomagnesemia (low serum magnesium) and potential Vitamin B-12 deficiency are labeled concerns for patients receiving prolonged therapy, often over several months or years.

Regulatory Safety Constraints

The medicine is contraindicated in individuals with known hypersensitivity to omeprazole or substituted benzimidazoles. Furthermore, the label requires the statement that symptomatic improvement does not preclude the presence of gastric malignancy, and temporary discontinuation is advised before certain diagnostic tests for neuroendocrine tumors.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that an overdose of Zatrol (Omeprazole) typically results in symptoms that are transient and are generally classified as not life-threatening, even following the reported ingestion of very high single doses.

Documented Manifestations

Overdose may present with several effects affecting various body systems. Documented manifestations include gastrointestinal distress (nausea, vomiting, diarrhea, abdominal pain) and Central Nervous System (CNS) effects such as headache, confusion, and drowsiness. Other noted signs include tachycardia (unusually fast heartbeat), flushing, increased sweating, and blurred vision.

Required Emergency Actions

Given that no specific antidote is known for Zatrol overdose, all regulatory guidance mandates that treatment must be symptomatic and supportive. It is required to seek immediate medical attention and contact a Poison Control Center right away if an overdose is suspected. Urgent medical services must be called immediately if the individual collapses, has a seizure, or has trouble breathing. Immediate action is especially critical for pediatric patients. Supportive clinical management may include monitoring of vital signs and potential procedures such as gastric lavage or the administration of activated charcoal to reduce drug absorption.

Therapeutic Uses of Zatrol

What Zatrol Treats: Main Uses and Benefits

The core use of Zatrol (Omeprazole) is to provide symptomatic relief and therapeutic support across conditions involving heightened gastric acid production. The medication is applied across domains where additional symptomatic support is needed, primarily as it is commonly used to help with symptoms related to heightened physiological activity.


Managing Persistent Heartburn and Acid Reflux

Zatrol is commonly used to help manage symptoms related to acid-induced irritative states, including frequent heartburn, uncomfortable acid regurgitation, and epigastric discomfort. The therapeutic applications include supporting patients diagnosed with Gastroesophageal Reflux Disease (GERD), used for managing the healing of erosive esophagitis, and is relevant for the management of both duodenal and gastric ulcers. It is also relevant in the long-term management of rare, severe conditions like Zollinger-Ellison Syndrome and as a component in combination therapy used to manage H. pylori infection.

The medication offers symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to improved day-to-day comfort during symptomatic periods. The supportive benefit is key as it is relevant for easing the symptoms related to inflammatory or irritative states.

Quick Fact: Relief for Acid-Related Discomfort
Primary Role Provides supportive relief when symptoms interfere with routine activities.
Typical Context Used in conditions involving episodic or fluctuating manifestations of gastric acid.
Core Benefit Helps ease the overall symptom burden associated with heartburn and acid damage.

Support for Tissue Repair and Specialized Management

Zatrol is applied in conditions marked by tissue injury, such as peptic ulcers and erosive esophagitis. Its use may assist with sustained acid suppression, supporting the healing and repair of these tissues, which ultimately may assist with maintaining functional stability and addresses underlying epigastric pain and difficulty swallowing. This supportive role is relevant in clinical settings marked by heightened distress, and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview of Omeprazole

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility requirements for Zatrol (Omeprazole) as defined by governmental regulatory documents.

Category Official Regulatory Statement
Populations for whom use is contraindicated: Patients with known hypersensitivity to omeprazole, substituted benzimidazoles, or any component of the formulation; and patients receiving rilpivirine-containing products [U.S. FDA, EMA].
Age-related eligibility rules: Safety and effectiveness have not been established for children younger than one year of age [U.S. FDA]. Use is established for adults and for pediatric patients aged one year and older for specific indications.
Condition-specific eligibility rules: Severe Hepatic Impairment may require dose adjustment or monitoring. Renal Impairment does not necessitate a dose adjustment [EMA/SmPC].
Pregnancy and lactation eligibility status: Pregnancy: Omeprazole can be used; major malformative risks are considered unlikely. Lactation: Excreted into human milk, but not expected to be harmful to the infant when used at therapeutic doses [NIH/LactMed, EMA].
Eligibility-related restrictions: In adults, symptomatic response to the medicine does not preclude the presence of gastric malignancy, requiring pre-treatment evaluation [U.S. FDA].

The official label strictly prohibits Zatrol use in patients with specific allergies or those taking certain antiviral medications. Eligibility for children is defined by minimum age thresholds, while use in adults is conditional upon ruling out severe underlying conditions like gastric malignancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zatrol (alfuzosin) has the potential to interact with several other medicinal products, primarily by either increasing its own concentration in the blood or by adding to its blood-pressure-lowering effects.

Combinations that must be avoided (Contraindicated):

Interacting Product Category Example Medicines Reason for Restriction
Other Alpha-1 Receptor Blockers Prazosin, Tamsulosin, Doxazosin Increased risk of severely low blood pressure (hypotension).
Potent CYP3A4 Inhibitors Ketoconazole, Itraconazole, Ritonavir Increases the level of Zatrol in the blood, which can lead to increased side effects, including severe hypotension.

Combinations to be used with caution (Increased Risk):

  • Antihypertensive Medicines and Nitrates: Concomitant use with drugs used to lower blood pressure or treat heart conditions (such as nitrates) may result in an additive hypotensive effect, increasing the risk of low blood pressure and fainting.
  • Phosphodiesterase-5 (PDE5) Inhibitors: Combining with medicines like sildenafil or tadalafil can potentially cause symptomatic hypotension, as both classes of drugs are vasodilators.
  • Medicines that Prolong the QT Interval: Caution is advised, especially in patients with a personal or family history of QT prolongation, as Zatrol has been observed to slightly increase the QT interval.
  • General Anesthetics: Profound hypotension may occur during surgery; it is generally recommended to withdraw Zatrol treatment 24 hours prior to a planned surgery requiring general anesthesia.

Mechanism of Action

Blocking Alpha-1 Adrenergic Receptors

Zatrol operates as a selective antagonist (blocker) primarily targeting alpha1-adrenergic receptors. These receptors are densely concentrated on the smooth muscle cells within the lower urinary tract system, including the prostate gland and the bladder neck. The drug molecules bind to these receptor sites, thereby preventing their activation by endogenous neurotransmitters, such as norepinephrine.

Modulating Lower Urinary Tract Muscle Tone

The binding interaction interrupts the intracellular signaling cascade that normally initiates calcium-dependent smooth muscle contraction in the affected tissues. The primary pathway consequence is the induction of muscle relaxation. This mechanistic cascade results in the physiological consequence of reduced muscle tone and a corresponding decrease in pressure across the tissues of the lower urinary tract.

Dosage and Administration Information

How Zatrol is Used

Zatrol (Omeprazole) is primarily administered via the oral route as a delayed-release capsule or tablet. The medicine is typically taken once daily in the morning, specifically before eating, to align with its proper use.

The official instructions mandate that the delayed-release form must be swallowed whole to preserve the integrity of the active ingredient. It is strictly prohibited to crush or chew the tablet or capsule. If swallowing whole is not possible, the capsule contents (pellets) may be mixed with a small amount of applesauce or an acidic liquid, but this mixture must be swallowed immediately without chewing. In situations where oral intake is temporarily impossible, the intravenous (IV) route is an approved alternative.

Standard Administration Patterns

Administration Feature Official Instruction
Dosing Frequency Once daily (qDay) for most standard uses. Twice daily for H. pylori regimens.
Course Duration Short-term (e.g., 4 to 8 weeks) or long-term for maintenance (up to 12 months) and certain pathological conditions.
Dose Adjustments No adjustment is required for older adults or renal impairment; a dose reduction is mandatory for patients with severe hepatic impairment.

The dose ranges from 20 mg to 40 mg for most standard adult uses, while certain pathological conditions may require highly individualized doses up to 360 mg per day, which must be administered in divided doses.

Recent Clinical Evidence

Zatrol: Recent Clinical Evidence

Research has investigated the use of Zatrol, with studies focusing on its profile and patient outcomes.


Investigating Symptom Management

Research has investigated the use of this drug as a treatment option, exploring its potential profile in relation to motor symptoms. Studies included patients with advanced symptoms to evaluate the drug’s profile.

  • Motor Symptoms: Early studies evaluated the drug in relation to motor symptoms, with a focus on patients experiencing various disease-related symptoms. One set of studies examined the combination for its potential profile concerning motor symptoms, specifically looking at changes over a defined treatment period.
  • Pain and Stiffness: One area of investigation involved assessing outcomes related to symptoms like pain and stiffness. Research has examined the drug's profile regarding the timing of observed symptomatic changes in this area. Results from ongoing trials are still being gathered, and long-term data collection is continuing.
  • Quality of Life: Researchers examined how the drug related to patient-reported quality of life measures, focusing on daily activities and overall well-being.

Safety and Patient Profile

Clinical trial data examined the drug’s safety and how it was managed by different patients across different patient groups.

  • Tolerability: Studies assessed common side effects and the frequency of adverse events across the patient cohort.
  • Patient Groups: Sub-group analyses examined the drug’s profile in patients with specific comorbidities or those taking other medications.

Key Studies & References Guideline on Lower Urinary Tract Symptoms in Men (Alpha-Blockers, Relevant to Drug Profile and Patient Groups)

Frequently Asked Questions (FAQ)

Common questions about Zatrol (FAQ)

Q: How quickly do people usually start to notice Zatrol working?

Official regulatory information indicates that the anti-acid effect typically begins within one hour after the first dose, reaching its maximum strength in about two hours. The full, sustained benefit is generally observed after four days of continuous daily use, as the inhibitory effect increases with repeated dosing.

Q: Does taking Zatrol cause changes in weight for most people?

According to official post-marketing safety data, a change such as weight increase has been documented as a very rare adverse reaction. This means it has been reported with an extremely low incidence (less than 0.01%) and is not considered a common expectation of using the medicine.

Q: Is Zatrol considered a controlled substance?

No. Regulatory documents state that this medication is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or similar government bodies.

Q: What should be done if someone accidentally takes too much Zatrol, according to official documents?

Official patient information indicates that if a person takes too much of this medicine, they are advised to immediately contact a poison control center or seek treatment at the nearest emergency room.

Q: Can Zatrol still be taken if a dose is missed?

Official instructions state that if a dose is missed, it can be taken as soon as you remember. Regulatory guidelines state that if it is almost time for the next scheduled dose, the missed dose is typically skipped, and the guidelines advise against taking two doses at the same time.

Q: How long does Zatrol stay in the body after the last use?

The medicine is quickly removed from the bloodstream. Product information notes that the half-life is less than one hour, and the drug is generally cleared from the plasma within 3–4 hours, although its effect on acid production lasts much longer.

Q: Does Zatrol have a 'black box' warning from the FDA or similar agency?

The official product label does not currently include an FDA Black Box Warning. However, regulatory documents do contain explicit warnings about serious potential risks, including an increased chance of Clostridium difficile-associated diarrhea, bone fracture, and low magnesium levels.

Q: Is it true that Zatrol can sometimes change the color of urine?

Safety documents have rarely reported the side effect of "bloody or cloudy urine" in post-marketing data. A general, non-specific change in urine color is not explicitly listed as a reported adverse reaction.

Q: Does Zatrol interact with birth control pills?

According to official prescribing information, there have been no known clinically significant drug-drug interactions documented between this medicine and standard oral contraceptive pills.

Q: Are there any known interactions between Zatrol and commonly used vitamins or supplements?

Regulatory warnings state that daily, long-term use (e.g., over three years) may be associated with a risk of Vitamin B-12 deficiency. Additionally, regulatory guidance indicates that the use of the herbal supplement St. John’s Wort is typically avoided due to a potential drug interaction.

Q: What are the general research findings regarding Zatrol's effectiveness?

Official documents include summaries of clinical studies that support the drug’s approved uses, such as its effectiveness in healing damage from erosive esophagitis and treating symptoms of gastroesophageal reflux disease (GERD). These findings confirm its purpose as an acid reducer.

Q: Why do some people say Zatrol makes them feel drowsy?

Regulatory safety reviews have noted that somnolence (drowsiness) and dizziness are reported adverse reactions in clinical use. While they may not be common for all users, these documented possibilities can contribute to a feeling of being tired or unwell.

Q: Are there any specific dietary restrictions mentioned for Zatrol?

The primary instruction related to diet is that the medicine should be taken before a meal. Beyond this administration timing and the specific warning against the supplement St. John's Wort, official prescription labels do not typically list general dietary restrictions.

Q: Why do official sources sometimes mention liver function tests for Zatrol users?

Official documents explain that the medicine is extensively processed by the liver, and its proper clearance may be reduced in patients with existing liver issues. Elevated liver enzymes and hepatitis are also listed as reported adverse reactions, which is why liver function may be monitored.

Q: Can Zatrol affect a person's ability to drive or operate machinery?

Generally, regulatory advice indicates that the medication does not typically affect a person’s ability to drive. However, if a user experiences side effects like dizziness or visual disturbances, regulatory materials note that operating vehicles or complex machinery may be cautioned against.

Q: What should users know about discontinuing Zatrol according to official advice?

Official patient information emphasizes that dosage changes or cessation of the medication should only be done after consulting with a healthcare provider. This reflects the general regulatory advice on discontinuing treatment.

Q: Does Zatrol require any special monitoring while being used?

Yes, official warnings and precautions indicate that monitoring may be recommended for certain risks associated with prolonged use. This can include checking magnesium levels (hypomagnesemia) and Chromogranin A (CgA) levels.

Q: What is the mechanism of action of Zatrol?

The drug belongs to the class of proton pump inhibitors (PPIs). According to official documents, it works by suppressing gastric acid secretion through the inhibition of the H^+/ K^+ ATPase enzyme system, commonly called the "proton pump," in the stomach lining.

Q: What is the pregnancy category rating for Zatrol?

Before the FDA transitioned to the current labeling rule, this drug was categorized as Pregnancy Category C. This indicated that animal studies had shown some adverse effects on the fetus, but there was a lack of adequate, well-controlled studies in pregnant humans.

Q: Does Zatrol work for nerve pain or muscle pain?

Official indications for this drug relate only to the reduction of stomach acid and the treatment of gastrointestinal conditions like GERD and ulcers. Nerve pain and muscle pain are not among the approved uses listed in regulatory documents.

Q: Can Zatrol be taken with food, as specified in the instructions?

Regulatory dosage instructions indicate that the delayed-release capsule form is typically taken before a meal, usually with a glass of water, rather than being taken during or immediately after eating.

How should Zatrol be stored and disposed of?

The storage and disposal of Zatrol (Omeprazole) must strictly adhere to official regulatory requirements to maintain product stability and safety.

Required Storage Conditions

Zatrol must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory that the medicine be protected from moisture and humidity to preserve the integrity of the delayed-release formulation; therefore, storage in damp areas like the bathroom is prohibited.

Store the product in its original container with the cap tightly closed, and do not freeze the medication. The medicine must be stored out of the sight and reach of children.

Official Disposal Instructions

Disposal of unused or expired Zatrol should prioritize official drug take-back programs. If a program is unavailable, unused medication must be prepared for household trash by mixing it with an undesirable substance (e.g., used coffee grounds) and sealing it in a plastic bag. Do not flush this medicine down a toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zatrol found in:

A-Z Index: